Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity

Drug Metabolism and Disposition

Volumn 28, Issue 1, 2000, Pages 28-33

  Kharasch, Evan D ^a   Hankins, Douglas C ^b   Taraday, Julie K ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; METHOXSALEN; UMBELLIFERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTICOAGULANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; METHOXSALEN; MIXED FUNCTION OXYGENASES; MOLECULAR PROBES; UMBELLIFERONES;

EID: 0033960956     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Berkman CE, Park SB, Wrighton SA and Cashman JR (1995) In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 50:565-570.
2. Billard V, Gambus PL, Barr J, Minto CF, Corash L, Tessman JW, Stickney JL and Shafer SL (1995) The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. Br J Clin Pharmacol 40:347-360.
3. Bourrié M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
4. Busch U, Schmid J, Koss FW, Zipp H and Zimmer A (1978) Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog. Arch Dermatol Res 262:255-265.
5. Caroldi S, De Paris P, Zotti S, Zanella I and Brugnone F (1994) Effects of disulfiram on serum dopamine-β-hydroxylase and blood carbon disulphide concentrations in alcoholics. J Appl Toxicol 14:77-80.
6. Chen W, Koenigs LL, Thompson SJ, Peter RM, Rettie AE, Trager WF and Nelson SD (1998) Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol 11:295-301.
7. Clarke SE, Ayrton AD and Chenery RJ (1994) Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24:517-526.
8. Crespi CL, Penman BW, Leakey JAE, Arlotto MP, Stark A, Parkinson A, Turner T, Steimel DT, Rudo K, Davies RL and Langenbach R (1990) Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11:1292-1300.
9. Draper AJ, Madan A and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
10. Faiman MD, Jensen JC and Lacoursiere RB (1984) Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 36:520-526.
11. Georgiew S, Groger H and Flood MK (1978) Comparative serum and tonsillar tissue concentration of two macrolides. J Antimicrob Chemother 4:472-473.
12. Guengerich FP, Kim D-H and Iwasaki M (1991) Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
13. Herfst MJ and De Wolff FA (1983) Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clin Pharmacol Ther 34:117-124.
14. Honkakoski P and Negishi M (1997) The structure, function and regulation of cytochrome P450 2A enzymes. Drug Metab Rev 29:977-996.
15. Jensen JC, Faiman MD and Hurwitz A (1982) Elimination characteristics of disulfiram over time in five alcoholic volunteers: A preliminary study. Am J Psychiatry 139:1596-1598.
16. Johansson B and Stankiewicz Z (1989) Inhibition of erythrocyte aldehyde dehydrogenase activity and elimination kinetics of diethyldithiocarbamic acid methyl ester and its monothio analogue after administration of single and repeated doses of disulfiram to man. Eur J Clin Pharmacol 37:133-138.
17. Kharasch ED, Hankins DC, Baxter PJ and Thummel KE (1998) Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 64:39-45.
18. Kharasch ED, Hankins D, Mautz D and Thummel KE (1996) Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 347:1367-1371.
19. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA and Cox K (1997) The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87:36-50.
20. Kharasch ED, Thummel K, Mhyre J and Lillibridge J (1993) Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin Pharmacol Ther 53:643-650.
21. Koenigs LL, Peter RM, Thompson SJ, Rettie AE and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
22. Koenigs LL and Trager WF (1998) Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37:10047-10061.
23. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
24. Madan A, Parkinson A and Faiman MD (1998) Identification of the human P-450 enzymes responsible for the sulfoxidalion and thiono-oxidation of diethyldithiocarbamate methyl ester: Role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 22:1212-1219.
25. Maenpaa J, Juvonen R, Raunio H, Rautio A and Pelkonen O (1994) Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem Pharmacol 48:1363-1369.
26. Messina ES, Tyndale RF and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
27. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T and Kuroiwa Y (1996a) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010-1015.
28. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T and Kuroiwa Y (1996b) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
29. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors. Evaluations of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
30. Nunoya K, Yokoi Y, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C and Kamataki T (1996) (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J Pharmacol Exp Ther 277:768-774.
31. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
32. Oscarson M, Gullsten H, Rautio A, Bernal ML, Sinues B, Dahl ML, Stengard JH, Pelkonen O, Raunio H and Ingelman-Sundberg M (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 438:201-205.
33. Pearce R, Greenway D and Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol and testosterone oxidation. Arch Biochem Biophys 298:211-225.
34. Periti P, Mazzei T, Mini E and Novelli A (1992) Pharmacokinetic drug interactions of macrotides, Clin Pharmacokinet 23:106-131.
35. Sadeque AJM, Fisher MB, Korzekwa KR, Gonzalez FJ and Rettie AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283:698-703.
36. Saïd A, Makki S, Muret P, Toubin G, Humbert P and Millet J (1997) Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinelic in patients' serum. Exp Dermatol 6:51-63.
37. Schmid J, Prox A, Zipp H and Koss FW (1980) The use of stable isotopes to prove the saturable first-pass effect of methoxsalen. Biomed Mass Spectram 7:560-564.
38. Sesardie D, Boobis AR, Murray BP, Murray S, Segura J, De La Torre R and Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663.
39. Spracklin D, Hankins DC, Fisher JM, Thummel KE and Kharasch ED (1997) Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism. J Pharmacol Exp Ther 281:400-411.
40. m isoforms. Drug Metab Dispos 26:605-608.
41. Sullivan TJ, Walter JL, Kouba RF and Maiwald DC (1986) Bioavailability of a new oral methoxsalen formulation. Arch Dermatol 122:768-771.
42. Tamis E, Cami J, Roberts DJ, Spickett RGW, Celdran E and Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9-18.
43. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH and Miners JO (1994) Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenctics 4:281-284.
44. Thomton-Manning JR, Nikula KJ, Hotchkiss JA, Avila KJ, Rohrbacher KD, Ding X and Dahl AR (1997) Nasal cytochrome P450 2A: Identification, regional localization and metabolic activity toward hexamethylphosphoramide, a known nasal carcinogen. Toxicol Appl Pharmacol 142:22-30.
45. Tinel M, Belghiti J, Descatoire V, Amouyal G, Letteron P, Geneve J, Larrey D and Pessayre D (1987) Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem Pharmacol 36:951-955.
46. Walther T and Haustein U-F (1991) 8-methoxypsoralen serum levels in poor responders to photochemotherapy. Pharmacol Ther 30:516-518.
47. Yamazaki H and Shimada T (1998) Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6β-hydroxylation by roxithromycin and its metabolites, troleandomycin and erythromycin. Drug Metab Dispos 26:1053-1057.